Statement Of Cash Flows [Abstract]

Embla Medical hf - Filing #5889952

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
682,000 USD
68,960,000 USD
68,278,000 USD
68,278,000 USD
58,801,000 USD
412,000 USD
58,389,000 USD
58,389,000 USD
Adjustments to reconcile profit (loss) [abstract]
Adjustments for decrease (increase) in inventories
5,928,000 USD
2,268,000 USD
Adjustments for decrease (increase) in trade accounts receivable
5,524,000 USD
16,370,000 USD
Adjustments for decrease (increase) in other operating receivables
1,828,000 USD
2,214,000 USD
Adjustments for increase (decrease) in trade accounts payable
2,279,000 USD
14,896,000 USD
Adjustments for provisions
3,174,000 USD
7,365,000 USD
Cash flows from (used in) operations
160,397,000 USD
125,986,000 USD
Interest paid, classified as operating activities
24,082,000 USD
16,046,000 USD
Interest received, classified as operating activities
3,238,000 USD
4,733,000 USD
Income taxes paid (refund), classified as operating activities
23,487,000 USD
20,349,000 USD
Cash flows from (used in) operating activities
116,066,000 USD
94,324,000 USD
Cash flows from (used in) investing activities [abstract]
Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities
70,072,000 USD
11,903,000 USD
Other inflows (outflows) of cash, classified as investing activities
4,529,000 USD
2,966,000 USD
Cash flows from (used in) investing activities
104,770,000 USD
57,147,000 USD
Cash flows from (used in) financing activities [abstract]
Payments from changes in ownership interests in subsidiaries that do not result in loss of control
9,648,000 USD
0 USD
Payments of lease liabilities, classified as financing activities
24,379,000 USD
25,423,000 USD
Cash flows from (used in) financing activities
5,761,000 USD
40,959,000 USD
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
17,056,000 USD
3,782,000 USD
Cash and cash equivalents
86,163,000 USD
72,653,000 USD
76,631,000 USD

Talk to a Data Expert

Have a question? We'll get back to you promptly.